GB0321620D0 - Quinazoline derivatives - Google Patents

Quinazoline derivatives

Info

Publication number
GB0321620D0
GB0321620D0 GBGB0321620.7A GB0321620A GB0321620D0 GB 0321620 D0 GB0321620 D0 GB 0321620D0 GB 0321620 A GB0321620 A GB 0321620A GB 0321620 D0 GB0321620 D0 GB 0321620D0
Authority
GB
United Kingdom
Prior art keywords
quinazoline derivatives
quinazoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0321620.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0321620.7A priority Critical patent/GB0321620D0/en
Publication of GB0321620D0 publication Critical patent/GB0321620D0/en
Priority to DE602004013806T priority patent/DE602004013806D1/en
Priority to JP2006526682A priority patent/JP4795952B2/en
Priority to US10/573,090 priority patent/US7569577B2/en
Priority to ES04768469T priority patent/ES2305844T3/en
Priority to PCT/GB2004/003923 priority patent/WO2005026150A1/en
Priority to SI200430769T priority patent/SI1667991T1/en
Priority to CA2538884A priority patent/CA2538884C/en
Priority to EP04768469A priority patent/EP1667991B1/en
Priority to PL04768469T priority patent/PL1667991T3/en
Priority to RU2006112599/04A priority patent/RU2378268C2/en
Priority to DK04768469T priority patent/DK1667991T3/en
Priority to PT04768469T priority patent/PT1667991E/en
Priority to MXPA06002964A priority patent/MXPA06002964A/en
Priority to AU2004272348A priority patent/AU2004272348B2/en
Priority to UAA200604148A priority patent/UA84167C2/en
Priority to BRPI0414489A priority patent/BRPI0414489A8/en
Priority to AT04768469T priority patent/ATE395346T1/en
Priority to KR1020067007266A priority patent/KR101244524B1/en
Priority to CN200480033525XA priority patent/CN1882567B/en
Priority to TW093127785A priority patent/TW200519104A/en
Priority to ARP040103321A priority patent/AR045663A1/en
Priority to IL174261A priority patent/IL174261A0/en
Priority to ZA200602191A priority patent/ZA200602191B/en
Priority to NO20061322A priority patent/NO20061322L/en
Priority to CO06034940A priority patent/CO5690594A2/en
Priority to HK06111949A priority patent/HK1091480A1/en
Priority to HR20080329T priority patent/HRP20080329T3/en
Priority to CY20081100724T priority patent/CY1108186T1/en
Priority to US12/482,620 priority patent/US20090312343A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0321620.7A 2003-09-16 2003-09-16 Quinazoline derivatives Ceased GB0321620D0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GBGB0321620.7A GB0321620D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives
CN200480033525XA CN1882567B (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
AU2004272348A AU2004272348B2 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
BRPI0414489A BRPI0414489A8 (en) 2003-09-16 2004-09-13 quinazoline derivative, pharmaceutical composition, use of a quinazoline derivative, and process for the preparation of a quinazoline derivative
JP2006526682A JP4795952B2 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
ES04768469T ES2305844T3 (en) 2003-09-16 2004-09-13 DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASE.
PCT/GB2004/003923 WO2005026150A1 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
SI200430769T SI1667991T1 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
CA2538884A CA2538884C (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
EP04768469A EP1667991B1 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
PL04768469T PL1667991T3 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
RU2006112599/04A RU2378268C2 (en) 2003-09-16 2004-09-13 Quinoline derivatives as tyrosine kinase inhibitors
DK04768469T DK1667991T3 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
PT04768469T PT1667991E (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
MXPA06002964A MXPA06002964A (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors.
DE602004013806T DE602004013806D1 (en) 2003-09-16 2004-09-13 Chinazolinderivate als tyrosinkinaseinhibitoren
UAA200604148A UA84167C2 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors, process for the preparation thereof (variants), pharmaceutical composition based thereon
US10/573,090 US7569577B2 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
AT04768469T ATE395346T1 (en) 2003-09-16 2004-09-13 QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
KR1020067007266A KR101244524B1 (en) 2003-09-16 2004-09-13 Quinazoline derivatives as tyrosine kinase inhibitors
TW093127785A TW200519104A (en) 2003-09-16 2004-09-14 Quinazoline derivatives
ARP040103321A AR045663A1 (en) 2003-09-16 2004-09-16 QUINAZOLINE DERIVATIVES
IL174261A IL174261A0 (en) 2003-09-16 2006-03-12 Quinazoline derivatives as tyrosine kinase inhibitors
ZA200602191A ZA200602191B (en) 2003-09-16 2006-03-15 Quinazoline derivatives as tyrosine kinase inhibitors
NO20061322A NO20061322L (en) 2003-09-16 2006-03-23 Quinazoline derivatives as tyrosine kinase inhibitors
CO06034940A CO5690594A2 (en) 2003-09-16 2006-04-10 DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASE
HK06111949A HK1091480A1 (en) 2003-09-16 2006-10-31 Quinazoline derivatives as tyrosine kinase inhibitors
HR20080329T HRP20080329T3 (en) 2003-09-16 2008-07-07 Quinazoline derivatives as tyrosine kinase inhibitors
CY20081100724T CY1108186T1 (en) 2003-09-16 2008-07-10 QUINAZOLINE DERIVATIVES AS TYROSINE MINE INSPECTORS
US12/482,620 US20090312343A1 (en) 2003-09-16 2009-06-11 Quinazoline derivatives as tyrosine kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321620.7A GB0321620D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
GB0321620D0 true GB0321620D0 (en) 2003-10-15

Family

ID=29227141

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0321620.7A Ceased GB0321620D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives

Country Status (4)

Country Link
KR (1) KR101244524B1 (en)
CN (1) CN1882567B (en)
GB (1) GB0321620D0 (en)
ZA (1) ZA200602191B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102452988B (en) 2010-10-27 2016-01-27 中国科学院化学研究所 A kind of quinazoline derivant and preparation method thereof
TWI592417B (en) * 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 Prodrugs of amino quinazoline kinase inhibitor
TWI567063B (en) * 2014-09-05 2017-01-21 國立交通大學 A compound for promoting apoptosis of cancer cells, a pharmaceutical composition containing the same and uses thereof
CN108078990B (en) * 2016-11-23 2023-06-02 山东轩竹医药科技有限公司 New application of quinazoline derivative tyrosine kinase inhibitor
AR113451A1 (en) * 2017-10-18 2020-05-06 Spectrum Pharmaceuticals Inc INHIBITORS OF TYROSINE KINASES FROM THE FAMILY OF EGFR MUTANTS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188254T3 (en) * 1998-11-19 2003-06-16 Warner Lambert Co N- (4- (3-CHLORO-4-FLUORO-PHENYLAMINE) -7- (3-MORFOLIN-4-IL-PROPOXI) -QUIN AZOLIN-6-IL) -ACRILAMADA, AN IRREVERSIBLE THYROSINE KINASE INHIBITOR.
WO2002092578A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
KR101244524B1 (en) 2013-03-19
CN1882567A (en) 2006-12-20
CN1882567B (en) 2010-12-15
KR20070023631A (en) 2007-02-28
ZA200602191B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
GB0322409D0 (en) Quinazoline derivatives
IL174534A0 (en) Quinazoline derivatives
HK1091479A1 (en) Quinazoline derivatives
ZA200602264B (en) Quinazoline derivatives
GB0321648D0 (en) Quinazoline derivatives
IL175421A0 (en) Quinazoline derivatives
IL174390A0 (en) Quinazoline derivatives
HK1111417A1 (en) Quinazoline derivatives
GB0215823D0 (en) Quinazoline derivatives
HK1107339A1 (en) Quinazoline derivatives
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1095590A1 (en) Quinazoline derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
GB0330002D0 (en) Quinazoline derivatives
ZA200603039B (en) Quinazoline derivatives
GB2410025B (en) Quinazolin-4-one derivatives
PL374817A1 (en) Quinazoline derivatives
GB0321620D0 (en) Quinazoline derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0322534D0 (en) Quinazoline derivatives
GB0309008D0 (en) Quinazoline derivatives
GB0322536D0 (en) Quinazoline derivatives
GB0317664D0 (en) Quinazoline derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)